2018
DOI: 10.1016/j.bbmt.2017.12.006
|View full text |Cite
|
Sign up to set email alerts
|

Viral Kinetic Correlates of Cytomegalovirus Disease and Death after Hematopoietic Cell Transplant

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2019
2019
2020
2020

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…For numerous viral infections, including influenza, viral load correlates with disease severity and secondary household attack rate [7][8][9] . Early studies suggest that peak viral load differentiates mild from severe COVID-19 10 .Furthermore, viral load monitoring during antiviral therapy is a mainstay for various human infections including HIV, hepatitis B, cytomegalovirus and hepatitis C infections [11][12][13][14][15][16][17] . Particularly for viruses such as SARS-CoV-2 for which severe clinical outcomes occur in a minority of patients, viral load may serve as a useful surrogate marker to design smaller, but still sufficiently powered treatment studies 4,10 .…”
mentioning
confidence: 99%
“…For numerous viral infections, including influenza, viral load correlates with disease severity and secondary household attack rate [7][8][9] . Early studies suggest that peak viral load differentiates mild from severe COVID-19 10 .Furthermore, viral load monitoring during antiviral therapy is a mainstay for various human infections including HIV, hepatitis B, cytomegalovirus and hepatitis C infections [11][12][13][14][15][16][17] . Particularly for viruses such as SARS-CoV-2 for which severe clinical outcomes occur in a minority of patients, viral load may serve as a useful surrogate marker to design smaller, but still sufficiently powered treatment studies 4,10 .…”
mentioning
confidence: 99%
“…The challenge to mitigate the multifaceted consequences of CMV in transplantation has been a driving force in clinical virology, immunology, and drug development, and advances in these fields have led to our enhanced understanding of CMV. Establishing that asymptomatic CMV replication (expressed as viremia or DNAemia) correlates with CMV end-organ disease and death in HCT recipients enabled the use of CMV viremia (or the initiation of preemptive therapy) as a surrogate endpoint in clinical trials for the evaluation of CMV antivirals in HCT recipients [5].…”
Section: (See the Major Article By Ljungman Et Al On Pages 1525-33)mentioning
confidence: 99%
“…The impact of letermovir exposure on viral kinetics merits further study. In a recent meta-analysis of viral kinetics during preemptive therapy, the maximum viral load and duration of viral load correlated with death [5]. In the letermovir Phase III trial, among patients with early cs-CMV-i (by Week 14 post-HCT), 84% of letermovir recipients had the maximum CMV viral load of <1000 IU/mL, compared to 28% of placebo recipients, suggesting potential differences in viral load kinetics [7].…”
Section: (See the Major Article By Ljungman Et Al On Pages 1525-33)mentioning
confidence: 99%